In a recent study analyzing KRAS, BRAF, NRAS, PIK3CA, and TP53 gene mutations in 210 rectal tumors, only TP53 mutation was associated with poor pathological tumor regression (23% vs 36%, p = 0.05) [42]. This evidence concerns the gene KRAS and neoplasm.